Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
PHASE-I TRIAL OF SEQUENTIAL CYCLOPHOSPHAMIDE, CYCLOSPORINE-A, AND INTERFERON-ALPHA IN PATIENTS WITH CANCER - ATTEMPT TO INDUCE AUTOLOGOUS GRAFT-VERSUS-HOST REACTION TO ELICIT AN ANTITUMOR RESPONSE
Autore:
REDMAN BG; CHOU TH; ZALUPSKI M; UBERTI J; FLAHERTY L; DAN M; SENSENBRENNER L;
Indirizzi:
3990 JOHN R,5 HUDSON DETROIT MI 48201 WAYNE STATE UNIV,SCH MED,DIV HEMATOL ONCOL DETROIT MI 00000 WAYNE STATE UNIV,SCH MED,DEPT PATHOL DETROIT MI 00000
Titolo Testata:
Journal of immunotherapy with emphasis on tumor immunology
fascicolo: 2, volume: 18, anno: 1995,
pagine: 115 - 118
SICI:
1067-5582(1995)18:2<115:PTOSCC>2.0.ZU;2-Y
Fonte:
ISI
Lingua:
ENG
Soggetto:
BONE-MARROW TRANSPLANTATION; LYMPHOCYTES-T; DISEASE; INTERLEUKIN-2; LEUKEMIA; GAMMA;
Keywords:
AUTOLOGOUS GVH; AUTOLOGOUS CTL;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
16
Recensione:
Indirizzi per estratti:
Citazione:
B.G. Redman et al., "PHASE-I TRIAL OF SEQUENTIAL CYCLOPHOSPHAMIDE, CYCLOSPORINE-A, AND INTERFERON-ALPHA IN PATIENTS WITH CANCER - ATTEMPT TO INDUCE AUTOLOGOUS GRAFT-VERSUS-HOST REACTION TO ELICIT AN ANTITUMOR RESPONSE", Journal of immunotherapy with emphasis on tumor immunology, 18(2), 1995, pp. 115-118

Abstract

Previous reports of autologous bone marrow transplant (auto-BMT) havedemonstrated that myeloablative therapy followed by cyclosporin A (CsA), with and without interferon (IFN), can generate autoreactive cytotoxic T lymphocytes (auto-CTL) with potential therapeutic benefit. Thisis the first report of an attempt to generate auto-CTL using CsA and IFN after a non-myeloablative regimen. Cyclophosphamide (CTX) 1,200 mg/m(2) i.v. day 1 was followed by CsA and IFN-alpha days 2-28, administered in a sequential three-step Phase I dose-escalation scheme. Patients were evaluated twice weekly for clinical evidence of graft-versus-host (GVH) reaction. Peripheral blood mononuclear cells (PBMCs) were obtained before treatment, at time of clinical GVH reaction, and days 21and 28, and analyzed for auto-CTL, natural killer (NK) cell, and lymphokine-activated killer (LAK) cell activity. Patients also underwent punch skin biopsy at the time of clinical GVH reaction or day 21 to identify histologic evidence of GVH. Fourteen patients completed therapy and were evaluable for immunologic studies and anti-tumor response. Noincrease in auto-CTL, NK cell, or LAK cell activity was seen. Clinical or histologic evidence of GVH reaction did not occur. We conclude that this myelosuppressive dose of CTX combined with CsA and IFN is unable to generate clinical or immunologic evidence of an auto-GVH reaction. Further efforts are warranted to evaluate other therapeutic attempts to generate auto-CTL with anti-tumor activity based on preliminary results of clinical benefit in auto-BMT.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 07/07/20 alle ore 22:28:58